Bellerophon Therapeutics names COO
This article was originally published in Scrip
Bellerophon Therapeutics, a clinical-stage biotherapeutics company, has appointed Amit Agrawal chief operating officer, effective 8 July, and Dr Naseem Amin an independent director of the company, effective 29 June. Mr Agrawal joins Bellerophon from Amgen, where, since 2012, he was director of strategy and corporate development. While at Amgen, Mr Agrawal worked across several areas of the business covering R&D, manufacturing operations, commercial planning and business development. Meanwhile, Dr Amin, who was also appointed to Bellerophon's audit committee, has broad industry experience in the biotech and medical device industries. Until 2014, he was chief scientific officer of Smith and Nephew, where he provided scientific leadership to the organization.